Noveris Health Sciences is trading now at CA$0.21, up 16.67%, alongside a 3.73% biotech-sector gain, suggesting sector support and volatile recovery trading rather than a confirmed fresh company-specific catalyst.
- On August 18, 2026, it fell 40.98% to CA$0.18.
- Noveris announced a USPTO patent allowance and a CA$146,000 research work order on August 18, but available coverage does not directly attribute today’s move to that release.